Developing new drugs to treat Ebola virus infections
Optimizing Ridaifen-B analogs as potential therapeutics for Ebola viruses
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-10893513
This study is working on developing new medicines to help prevent and treat Ebola virus infections, and it’s for anyone interested in finding better ways to fight this disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10893513 on ClinicalTrials.gov |
What this research studies
This research focuses on creating new small molecule inhibitors that target the Ebola virus, specifically designed to prevent and treat infections. The team will screen a library of compounds to identify effective drugs and then optimize these compounds for better efficacy. The research includes testing these optimized drugs in animal models to evaluate their effectiveness against the virus. The ultimate goal is to provide a new therapeutic option for Ebola virus disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of Ebola virus exposure, particularly in endemic regions.
Not a fit: Patients who are not at risk of Ebola virus infection or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for Ebola virus infections, potentially saving lives and reducing the severity of the disease.
How similar studies have performed: Previous research has shown promise in developing antiviral therapies for Ebola, indicating that this approach has potential for success.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RONG, LIJUN — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: RONG, LIJUN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.